ArticleAlzheimer's & dementia (Amsterdam, Netherlands)2021
Evaluation of the ATN model in a longitudinal memory clinic sample with different underlying disorders.
Article in Alzheimer's & dementia (Amsterdam, Netherlands), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Risk of conversion to mild cognitive impairment or dementia among subjects with amyloid and tau pathology: a systematic review and meta-analysis.Alzheimer's research & therapy · 2024Pooled it
- Silhouettes, number Location, and cube analysis tests from the VOSP battery reveal visual object and space perception deficits in early Alzheimer's disease.Scientific reports · 2025Article
- The relation of a cerebrospinal fluid profile associated with Alzheimer's disease with cognitive function and neuropsychiatric symptoms in sporadic cerebral amyloid angiopathy.Alzheimer's research & therapy · 2024Article
- Differentiation of Alzheimer's disease from other neurodegenerative disorders using chemiluminescence immunoassays measuring cerebrospinal fluid biomarkers.Frontiers in dementia · 2024Article
- ATN cerebrospinal fluid biomarkers in dementia with Lewy bodies: Initial results from the United States Dementia with Lewy Bodies Consortium.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Clinical characteristics of patients with suspected Alzheimer's disease within a CSF Aß-ratio grey zone.Neurological research and practice · 2023Article
- Should artificial intelligence be used in conjunction with Neuroimaging in the diagnosis of Alzheimer's disease?Frontiers in aging neuroscience · 2023Review
- Amyloid-β levels and cognitive trajectories in non-demented pTau181-positive subjects without amyloidopathy.Brain : a journal of neurology · 2022Observational
- β-Amyloid, Tau, Neurodegeneration Classification and Eligibility for Anti-amyloid Treatment in a Memory Clinic Population.Neurology · 2022Article
- Longitudinal change in ATN biomarkers in cognitively normal individuals.Alzheimer's research & therapy · 2022Article
- Different AT(N) profiles and clinical progression classified by two different N markers using total tau and neurofilament light chain in cerebrospinal fluid.BMJ neurology open · 2022Article
- Abnormal tau in amyloid PET negative individuals.Neurobiology of aging · 2022Article
- Evaluation of the ATN model in a longitudinal memory clinic sample with different underlying disorders.Alzheimer's & dementia (Amsterdam, Netherlands) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTo evaluate the usefulness of the 2018 NIA-AA (National Institute on Aging and Alzheimer's Association) research framework in a longitudinal memory clinic study with different clinical outcomes and underlying disorders.
methodsWe included 420 patients with mild cognitive impairment or subjective cognitive impairment. During the follow up, 27% of the patients converted to dementia, with the majority converting to Alzheimer's disease (AD) or mixed dementia. Based on the baseline values of the cerebrospinal fluid biomarkers, the patients were classified into one of the eight possible ATN groups (amyloid beta [Aβ] aggregation [A], tau aggregation reflecting neurofibrillary tangles [T], and neurodegeneration [N]).
resultsThe majority of the patients converting to AD and mixed dementia were in ATN groups positive for A (71%). The A+T+N+ group was highly overrepresented among converters to AD and mixed dementia. Patients converting to dementias other than AD or mixed dementia were evenly distributed across the ATN groups. DISCUSSION: Our findings provide support for the usefulness of the ATN system to detect incipient AD or mixed dementia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.